Accordingly, chronic 6- to 8-week dosing with cTfRMAb-EPO without the N292G mutation [15] or other cTfRMAb-based therapies [56] does not result in reticulocyte suppression in AD mouse models. This evidence concerns the gene EPO and Alzheimer disease.